Sells branded pharmaceutical formulations in India and abroad, and through mid-2026 also manufactured active pharmaceutical ingredients (APIs). Domestic Formulations is the largest segment — it markets chronic-therapy drugs under brands such as Naprosyn, launched a new Naprosyn ES (Naproxen + Esomeprazole) combination in July 2026 through a partnership with Archerchem, and is scaling an immunosuppressant portfolio. International Formulations exports formulations to overseas markets. The API business, which contributed Rs 95.06 crore (13.54% of FY26 consolidated revenue), is being transferred on a slump sale basis to a newly formed wholly owned subsidiary, RPG Active Pharma, in which PE investors are committing up to Rs 700 crore; the same subsidiary is separately acquiring 100% of Actis Generics for Rs 80 crore in cash. Raw materials (19.2% of revenue) and employees (20.0% of revenue) are the largest operating costs, with capex at 9.2% and depreciation at 3.0% of revenue. FY26 consolidated revenue totalled Rs 707.52 crore, with Domestic Formulations at Rs 483.5 crore growing 13.8% year-on-year while International Formulations declined 6.7%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Domestic Formulations, International Formulations, API (Active Pharmaceutical Ingredients) (14%). Branded formulations-focused Indian pharma company, mid-scale, with the API business being carved out into a separately funded subsidiary
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 708 |
| EBITDA (ex other income) | 151 |
| margin % | 21.3 |
| Owners' profit | 115 |
| EPS, as reported (₹) | 18.08 |
| ROE % · ROCE % | 19.0 · 24.5 |
| Debt / equity (x) | 0.03 |
| Cash from operations | 57 |
| Capex | (65) |
| ₹ crore | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 180 | 177 | 196 |
| Profit before tax | 29 | 40 | 41 |
| Net profit | 22 | 30 | 31 |
| EPS (₹) | 13.38 | 18.08 | 18.60 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · RPGAP subsidiary raises INR 243.33 crore from ILSF and Vistaject | fund raising | high | — | — |
| 4 Sept 2026 · RPG Life Sciences shares link to recording of Sept 3 analyst call | investor communications | low | — | — |
| 3 Sept 2026 · RPG Life Sciences sets API business update call for Sept 3 | investor communications | low | — | — |
| 2 Sept 2026 · RPG Life Sciences transfers API business to RPGAP; two acquisitions announced | investor communications | medium | — | — |
| 2 Sept 2026 · RPG Life Sciences schedules investors and analyst call for September 3 | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Subsidiary RPGAP to acquire Raghava Life Sciences API business for up to Rs 135 cr | strategic transactions | high | — | — |
| 2 Sept 2026 · RPG Active Pharma to buy Raghava's API business for up to Rs 135 crores via slump sale | strategic transactions | high | — | — |
| 2 Sept 2026 · Subsidiary to acquire Raghava API business for up to Rs 135 crores via slump sale | strategic transactions | high | — | — |
| 1 Sept 2026 · RPG Life Sciences cancels investor meet scheduled for Sept 2 | board shareholder meetings | low | — | — |
| 25 Aug 2026 · RPG Life Sciences to meet analysts at Elara India Dialogue 2026 | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|
| 13.0 |
| 12.1 |
| 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 53.9 | 28.9 | 131 of 169 | 23% |
| P/B | 7.4 | 3.3 | 138 of 163 | 15% |
| ROCE | 24.4 | 10.8 | 17 of 183 | 91% |
| ROE | 19.0 | 10.4 | 24 of 171 | 87% |
| Debt / Equity | 0.0 | 0.1 | 62 of 171 | 64% |
| EBITDA margin | 24.5 | 17.5 | 56 of 165 | 67% |
| Market cap | 4457 | 839 | 60 of 182 | 67% |
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
